Anti-CD22 (Inotuzumab Ozogamicin), Humanized Antibody

Anti-CD22 (Inotuzumab Ozogamicin), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is an antibody-drug conjugate that is directed to CD22 which is highly expressed on the surface of B cells. The conjugate consists of Anti-CD22 humanized monoclonal antibody that is linked to a cytotoxic drug N-acetyl-gamma-calicheamicin via 4-(4 acetylphenoxy) butanoic acid (acetyl butyrate) linker. Upon internalization in the cell, the drug is detached from the antibody by hydrolytic cleavage. The drug binds to the minor groove of the DNA and forms a diradical species. This diradical species abstracts hydrogen ions from the phosphodiester bonds of DNA and causes double-strand DNA breaks, which leads to cell cycle arrest and apoptosis of the tumorigenic cells. The original antibody-drug conjugate is approved by the FDA to treat acute myeloid leukemia. It is also approved to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Immunogen Sequence:Human CD22

Target Alternative Name:CMC 544, CMC-544, CMC544, PF-05208773, WAY-207294, Way 207294, SIGLEC2, SIGLEC-2

Species Reactivities:Human

Tag Line:The biosimilar is an antibody-drug conjugate that targets CD22 that is highly expressed on the B cell surface. Upon detachment from the antibody inside the cell, the drug causes double-stranded DNA breaks, which leads to cell cycle arrest, and apoptosis of tumor cells

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.